SCHEMBL1004686

SCHEMBL1004686

COC(=O)c1cccc(OC)c1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.56
ALDH1A1 P00352 3/20 0.56
CFTR P13569 1/20 0.56
KDM4E B2RXH2 5/20 0.53
POLB P06746 2/20 0.53
GAA P10253 4/20 0.53
TSHR P16473 2/20 0.53
MAPT P10636 2/20 0.53
MAPK1 P28482 1/20 0.53
CTSD P07339 1/20 0.51
SLC6A3 Q01959 1/20 0.49
LMNA P02545 1/20 0.48
KCNK3 O14649 1/20 0.46
KCNK9 Q9NPC2 1/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
CA5A P35218 1/20 0.46
ATM Q13315 1/20 0.46
CA12 O43570 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2895994 0.86 ALDH1A1 (0.67) HSD17B10ALDH1A1CFTRKDM4EPOLB
SCHEMBL28797885 0.86 HSD17B10 (0.53) HSD17B10ALDH1A1CFTRKDM4EPOLB
SCHEMBL12896661 0.85 GAA (0.54) HSD17B10ALDH1A1CFTRKDM4EPOLB
SCHEMBL148830 0.83 G6PD (0.60) HSD17B10ALDH1A1KDM4ETSHRMAPT
SCHEMBL587109 0.83 LMNA (0.51) HSD17B10ALDH1A1KDM4EGAAMAPT
SCHEMBL30852229 0.83 G6PD (0.60) HSD17B10ALDH1A1KDM4ETSHRMAPT
SCHEMBL165834 0.83 HTT (0.49) ALDH1A1KDM4EMAPTCTSDLMNA
SCHEMBL29665304 0.83 LMNA (0.51) HSD17B10ALDH1A1KDM4EGAAMAPT
SCHEMBL31038441 0.83 LMNA (0.66) HSD17B10ALDH1A1CFTRKDM4EPOLB
SCHEMBL148358 0.83 LMNA (0.66) HSD17B10ALDH1A1CFTRKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106554-A1 AFTERGLOW MATERIALS AND METHODS OF FABRICATION THEREOF NATIONAL UNIVERSITY OF SINGAPORE (SG) 2026-05-21 WO claimed
WO-2026106554-A1 AFTERGLOW MATERIALS AND METHODS OF FABRICATION THEREOF NATIONAL UNIVERSITY OF SINGAPORE (SG) 2026-05-21 WO disclosed
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 US disclosed
US-20260092076-A1 NOVEL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2026-04-02 US disclosed
US-20260092073-A1 NOVEL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2026-04-02 US disclosed
EP-4695243-A1 NLRP3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2026-02-18 EP disclosed
EP-4539855-A1 BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF Borah, Inc. (US) 2025-04-23 EP disclosed
CN-119343143-A Boron-containing pyrimidine compounds, compositions containing them, methods and uses thereof 博拉公司 2025-01-21 CN disclosed
EP-4467199-A2 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2024-11-27 EP disclosed
CN-118908957-A Small molecule inhibitors of NF- κB induced kinase 詹森药业有限公司 2024-11-08 CN disclosed
EP-1670768-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2006-06-21 EP disclosed
US-20050227975-A1 New long acting beta-2-agonists and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO disclosed
WO-2005037796-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2005-04-28 WO disclosed
EP-0147211-B1 4H-3,1-BENZOXAZIN-4-ONES AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION SYNTEX (U.S.A.) INC. (US) 1990-09-12 EP disclosed
US-4657893-A ANTIINFLAMMATORY AGENTS SYNTEX (U.S.A.) INC. (US) 1987-04-14 US disclosed
EP-0093922-B1 BENZOXAZIN-2-ONES, THEIR PREPARATION AND THERAPEUTIC AGENTS CONTAINING THESE COMPOUNDS Dr. Karl Thomae GmbH (DE) 1986-12-30 EP disclosed
EP-0147211-A2 4H-3,1-benzoxazin-4-ones and related compounds, pharmaceutical compositions containing them, and processes for their preparation SYNTEX (U.S.A.) INC. (US) 1985-07-03 EP disclosed
US-4518597-A THROMBOSIS, ARTERIOSCLEROSIS, ANTITUMOR, ANTICOAGULANTS DR. KARL THOMAE GMBH (DE) 1985-05-21 US disclosed
EP-0093922-A2 Benzoxazin-2-ones, their preparation and therapeutic agents containing these compounds Dr. Karl Thomae GmbH (DE) 1983-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227975-A1 New long acting beta-2-agonists and their use as medicaments ADRB2, ADRA2A, ADRB1 HSD17B10 3536/4885ALDH1A1 1311/4885CFTR 166/4885
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase IRAK3, IKBKB, IKBKG HSD17B10 1345/4885ALDH1A1 3824/4885CFTR 668/4885
US-20260092073-A1 NOVEL COMPOUNDS CBR1, CBR3, ARRB1 HSD17B10 720/4885ALDH1A1 430/4885CFTR 421/4885
US-20260092076-A1 NOVEL COMPOUNDS NOD1, NLRP3, ARRB1 HSD17B10 1150/4885ALDH1A1 622/4885CFTR 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.